On Wednesday, Neuberg Diagnostics Private Limited announced the successful merger of Neuberg Supratech Reference Laboratory, Ahmedabad, and Neuberg Anand Reference Laboratory, Bangalore. The consolidation, facilitated by an NCLT court-based procedure, bolsters Neuberg Diagnostics' standing as a significant player in the diagnostics industry.
The merger unites two prominent organizations under Neuberg Diagnostics with a strategic objective to streamline operations and enhance efficiency. As a result of the consolidation, over 80% of the total group revenue has been incorporated, providing a robust foundation for Neuberg Diagnostics to achieve exceptional milestones.
The company's ambitious target of reaching gross revenues exceeding Rs 1,000 crores (US $120+ Million) in the current fiscal year is anticipated to be supported by the merger. The unified front allows the company to expand its range of cutting-edge diagnostic services across India and beyond.
Neuberg Diagnostics has established several centers of excellence, including the Neuberg Centre for Genomics Medicine (NCGM), Neuberg Centre for Proteomics & Metabolomics (NCPM), and others. These centers position Neuberg at the forefront of personalized medicine innovation. Particularly, NCGM has emerged as a significant player in the genomic medicine market across South Asia, the Middle East, and Africa.
Dr. GSK Velu, Chairman and Managing Director of Neuberg Diagnostics, expressed his enthusiasm about the merger. "This merger marks a significant step forward in our journey to provide unparalleled healthcare solutions. By integrating these renowned laboratories, we reinforce our commitment to delivering excellence in diagnostics and patient care," he stated.
Following the merger, changes were made to Neuberg Diagnostics' senior management team. Dr. Sandip Shah was promoted to Joint Managing Director, while Dr. Sujay Prasad was promoted to Chief Medical Director. Mr. A. Ganesan will continue in his role as Vice Chairman of Neuberg Diagnostics. Dr. Velu emphasized the importance of the leadership team in the company's success, stating that their combined diagnostics experience of over 120 years will elevate Neuberg Diagnostics to new standards of excellence.
Looking ahead, Neuberg Diagnostics plans to undertake an Initial Public Offering (IPO) in late 2024 or early 2025. This move aligns with the company's growth strategy and is expected to attract additional resources for operational expansion, thereby preserving its leadership position in diagnostic innovation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.